4D Molecular Therapeutics Inc (US:FDMT) — Company Overview, News & Financial Data
4D Molecular Therapeutics designs AAV vectors for gene therapy, targeting genetic disorders with precision and innovative treatments.
4D Molecular Therapeutics Inc
4D Molecular Therapeutics (NASDAQ:FDMT) specializes in harnessing advanced genetic engineering technologies to design targeted and proprietary AAV vectors for gene therapy. Dedicated to unlocking new treatments for various genetic disorders, the company's innovative platform aims to advance the development of gene therapy products with higher precision and effectiveness. Central to its operations are the ongoing projects that focus on addressing conditions in ophthalmology, cardiology, pulmonology, and rare diseases. 4D Molecular Therapeutics' primary objective is to create transformative gene therapeutic solutions that can lead to significant improvements in treatment outcomes for patients worldwide, reflecting its commitment to both scientific innovation and patient care.
Snapshot
Operations
Products and/or services of 4D Molecular Therapeutics Inc
- Targeted and evolved AAV vectors for genetic disorders, employing their Therapeutic Vector Evolution platform to create custom vectors.
- 4D-310, a gene therapy for Fabry disease, utilizing a customized AAV vector designed for cardiac targeting.
- 4D-125, a treatment geared towards X-Linked Retinitis Pigmentosa, devised to rectify mutations in the RPGR gene.
- 4D-110, focused on treating choroideremia, using a specific AAV vector to target and deliver therapeutic genes.
- 4D-150, developed for age-related macular degeneration and diabetic macular edema, intending to inhibit multiple VEGF isoforms.
- Pipeline expansion into additional therapeutic areas including oncology, leveraging their vector evolution platform for broader applications.
4D Molecular Therapeutics Inc executive team
- Dr. John F. Milligan Ph.D.Executive Chairman
- Dr. David H. Kirn M.D.Co-Founder, President, CEO & Director
- Dr. Fariborz Kamal Ph.D.Chief Technical Advisor
- Ms. Theresa JankeCo-Founder & Chief of Staff
- Mr. Kristian Humer M.B.A.CFO & Principal Financial Officer
- Mr. Ashoo GuptaPrincipal Accounting Officer & Principal Financial Officer
- Julian PeiHead of Investor Relations & Corporate Finance
- Dr. Katy Barglow Ph.D.Chief Technical Officer
- Dr. Scott P. Bizily J.D., Ph.D.Chief Legal Officer & Corporate Secretary
- Dr. An Song Ph.D.Chief Translational Medicine Advisor